Hemispherx Biopharma
Pharmaceuticals, 2117 Sw Highway 484, Ocala, Florida, 55344, United States, 11-50 Employees
Who is HEMISPHERX BIOPHARMA
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemi...
Read More
-
Headquarters: 2117 Sw Highway 484, Ocala, Florida, 55344, United States
-
Date Founded: 1966
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from HEMISPHERX BIOPHARMA
Hemispherx Biopharma Org Chart and Mapping
Email
Phone
Peter Rodino
Chief Operating Officer, General Counsel and Executive Director of Governmental Relations
Ann Coverly
Director of Human Resources and Administration; Deputy Investor Relations Coordinator
Similar Companies to Hemispherx Biopharma
G&W Laboratories
-
501-1000
-
$ 250 Million to 500 Million
Wockhardt USA
-
51-200
-
$ 250 Million to 500 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Hemispherx Biopharma
Answer: Hemispherx Biopharma's headquarters are located at 2117 Sw Highway 484, Ocala, Florida, 55344, United States
Answer: Hemispherx Biopharma's official website is https://aimimmuno.com
Answer: Hemispherx Biopharma's revenue is $5 Million to $10 Million
Answer: Hemispherx Biopharma's SIC: 2834
Answer: Hemispherx Biopharma's NAICS: 325412
Answer: Hemispherx Biopharma has 11-50 employees
Answer: Hemispherx Biopharma is in Pharmaceuticals
Answer: Hemispherx Biopharma top competitors include: G&W Laboratories , Wockhardt USA
Answer: Hemispherx Biopharma contact info: Phone number: Website: https://aimimmuno.com
Answer: Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherxs flagship products include Alferon N Injection and the experimental therapeutics Ampligen. Ampligen is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherxs platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because Ampligen is experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. The FDA approval of Alferon N Injection is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Companys Alferon N approval in Argentina includes the use of Alferon N Injection (under the brand name Naturaferon) for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. The Company exclusively operates a GMP certified manufacturing facility in the United States for commercial products.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month